Therefore, a combination of BRAF inhibitor (dabrafenib) and MEK1/2 inhibitor (trametinib) was approved in early 2014 for the treatment of metastatic melanoma, to which incidences of resistance has already been observed [12, 13]. This evidence concerns the gene BRAF and metastatic melanoma.